Published in Scand J Infect Dis on January 01, 2007
Melanized fungi in human disease. Clin Microbiol Rev (2010) 2.89
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother (2008) 1.69
Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother (2012) 1.62
Fungal infections in primary immunodeficiencies. Eur J Pediatr (2007) 1.37
Chronic granulomatous disease. Pediatr Radiol (2010) 1.05
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2013) 0.96
Brain abscess caused by Phaeoacremonium parasiticum in an immunocompromised patient. J Clin Microbiol (2010) 0.91
Combination Antifungal Therapy in the Treatment of Scedosporium apiospermum Central Nervous System Infections. Case Rep Infect Dis (2013) 0.89
Use of Antifungal Combination Therapy: Agents, Order, and Timing. Curr Fungal Infect Rep (2010) 0.85
Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother (2011) 0.83
Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model. Antimicrob Agents Chemother (2013) 0.80
Targeted Disruption of Melanin Biosynthesis Genes in the Human Pathogenic Fungus Lomentospora prolificans and Its Consequences for Pathogen Survival. Int J Mol Sci (2016) 0.76
Locally extensive angio-invasive Scedosporium prolificans infection following resection for squamous cell lung carcinoma. Med Mycol Case Rep (2013) 0.76
Disseminated Scedosporium prolificans infection in a Labrador retriever with immune mediated haemolytic anaemia. Med Mycol Case Rep (2014) 0.75
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis (2010) 35.92
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis (2006) 14.63
Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med (2009) 10.60
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis (2006) 7.36
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis (2013) 6.60
Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int (2005) 5.49
Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother (2010) 5.35
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol (2005) 5.26
Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother (2006) 4.80
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. J Clin Microbiol (2004) 4.70
Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis (2002) 4.08
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother (2009) 3.82
Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother (2012) 3.80
Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis (2002) 3.65
A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis (2007) 3.39
Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev (2007) 3.18
Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase. Clin Infect Dis (2011) 3.06
A new marker of sepsis post burn injury?*. Crit Care Med (2014) 3.05
Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis (2007) 2.90
In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother (2002) 2.89
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis (2012) 2.88
Redefining extended-spectrum beta-lactamases: balancing science and clinical need. J Antimicrob Chemother (2008) 2.88
Aspergillus infections in transplant recipients. Clin Microbiol Rev (2005) 2.82
Interspecies spread of Klebsiella pneumoniae carbapenemase gene in a single patient. Clin Infect Dis (2009) 2.75
Disseminated phaeohyphomycosis: review of an emerging mycosis. Clin Infect Dis (2002) 2.70
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis (2003) 2.62
Community-associated extended-spectrum β-lactamase-producing Escherichia coli infection in the United States. Clin Infect Dis (2012) 2.58
Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis (2003) 2.45
Sequence-based identification of filamentous basidiomycetous fungi from clinical specimens: a cautionary note. J Clin Microbiol (2009) 2.44
Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis (2007) 2.31
Coproduction of novel 16S rRNA methylase RmtD and metallo-beta-lactamase SPM-1 in a panresistant Pseudomonas aeruginosa isolate from Brazil. Antimicrob Agents Chemother (2006) 2.23
Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A (2014) 2.20
Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev (2012) 2.18
Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol (2008) 2.16
Th17 cells mediate clade-specific, serotype-independent mucosal immunity. Immunity (2011) 2.15
Gram-negative resistance: can we combat the coming of a new "Red Plague"? Med J Aust (2013) 2.12
Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis (2012) 2.08
Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother (2008) 2.03
Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother (2006) 1.99
Insights into a multidrug resistant Escherichia coli pathogen of the globally disseminated ST131 lineage: genome analysis and virulence mechanisms. PLoS One (2011) 1.94
Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. Antimicrob Agents Chemother (2009) 1.94
Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother (2008) 1.89
Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis (2009) 1.87
In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother (2007) 1.85
Simple disk-based method for detection of Klebsiella pneumoniae carbapenemase-type beta-lactamase by use of a boronic acid compound. J Clin Microbiol (2008) 1.85
Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother (2010) 1.80
High prevalence of metallo-beta-lactamase and 16S rRNA methylase coproduction among imipenem-resistant Pseudomonas aeruginosa isolates in Brazil. Antimicrob Agents Chemother (2007) 1.78
Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother (2003) 1.77
In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J Antimicrob Chemother (2006) 1.74
Leptospirosis after recreational exposure to water in the Yaeyama islands, Japan. Am J Trop Med Hyg (2005) 1.73
Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis (2010) 1.73
Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect (2002) 1.71
Antibiotic resistance--what's dosing got to do with it? Crit Care Med (2008) 1.67
Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob Agents Chemother (2007) 1.66
In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother (2002) 1.65
Emergence of high levels of extended-spectrum-beta-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother (2009) 1.64
Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? Int J Antimicrob Agents (2007) 1.64
Multiresistant Gram-negative infections: a global perspective. Curr Opin Infect Dis (2010) 1.62
Zygomycosis. Infect Dis Clin North Am (2002) 1.58
The role of antifungal susceptibility testing in the therapy of candidiasis. Diagn Microbiol Infect Dis (2004) 1.58
Tigecycline Efflux as a Mechanism for Nonsusceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 1.57
Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis (2013) 1.56
Pseudallescheria boydii (Anamorph Scedosporium apiospermum). Infection in solid organ transplant recipients in a tertiary medical center and review of the literature. Medicine (Baltimore) (2002) 1.53
Multiclonal outbreak of Klebsiella pneumoniae producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. Antimicrob Agents Chemother (2008) 1.53
Infections with nontyphoidal Salmonella species producing TEM-63 or a novel TEM enzyme, TEM-131, in South Africa. Antimicrob Agents Chemother (2004) 1.52
Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J Clin Microbiol (2010) 1.51
Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet (2010) 1.49
β-Lactamase production in key gram-negative pathogen isolates from the Arabian Peninsula. Clin Microbiol Rev (2013) 1.45
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents (2010) 1.43
Integron-mediated multidrug resistance in a global collection of nontyphoidal Salmonella enterica isolates. Emerg Infect Dis (2009) 1.41
Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2003) 1.40
Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. Rev Iberoam Micol (2010) 1.40
The success of acinetobacter species; genetic, metabolic and virulence attributes. PLoS One (2012) 1.39
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet (2011) 1.39
Epidemiology and antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region: 2008 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). Int J Antimicrob Agents (2010) 1.35
Country-to-country transfer of patients and the risk of multi-resistant bacterial infection. Clin Infect Dis (2011) 1.35
Detection of plasmid-mediated class C beta-lactamases. Int J Infect Dis (2007) 1.34
Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis (2009) 1.34
Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. Clin Infect Dis (2012) 1.33
Identification and molecular characterisation of New Delhi metallo-β-lactamase-1 (NDM-1)- and NDM-6-producing Enterobacteriaceae from New Zealand hospitals. Int J Antimicrob Agents (2012) 1.33
Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother (2011) 1.32
Identification of 16S rRNA methylase-producing Acinetobacter baumannii clinical strains in North America. Antimicrob Agents Chemother (2007) 1.32
Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother (2009) 1.31
Infectious complications following transrectal ultrasound-guided prostate biopsy: new challenges in the era of multidrug-resistant Escherichia coli. Clin Infect Dis (2013) 1.27
A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms. Clin Infect Dis (2006) 1.26
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2011) 1.26
Community-acquired extended-spectrum beta-lactamase producers, United States. Emerg Infect Dis (2007) 1.26
Looking for risk factors for the acquisition of antibiotic resistance: a 21st-century approach. Clin Infect Dis (2002) 1.26
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2012) 1.25
Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a single institution over a 10-year period. J Clin Microbiol (2010) 1.25
Taxonomy and phylogeny of the Fusarium dimerum species group. Mycologia (2009) 1.24
Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis (2006) 1.23
Novel multilocus sequence typing scheme reveals high genetic diversity of human pathogenic members of the Fusarium incarnatum-F. equiseti and F. chlamydosporum species complexes within the United States. J Clin Microbiol (2009) 1.22
Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol (2011) 1.16
Epidemiological profile of linezolid-resistant coagulase-negative staphylococci. Clin Infect Dis (2006) 1.16
Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother (2011) 1.16